Requirement for IL-13 independently of IL-4 in experimental asthma - PubMed (original) (raw)
Requirement for IL-13 independently of IL-4 in experimental asthma
G Grünig et al. Science. 1998.
Abstract
The pathogenesis of asthma reflects, in part, the activity of T cell cytokines. Murine models support participation of interleukin-4 (IL-4) and the IL-4 receptor in asthma. Selective neutralization of IL-13, a cytokine related to IL-4 that also binds to the alpha chain of the IL-4 receptor, ameliorated the asthma phenotype, including airway hyperresponsiveness, eosinophil recruitment, and mucus overproduction. Administration of either IL-13 or IL-4 conferred an asthma-like phenotype to nonimmunized T cell-deficient mice by an IL-4 receptor alpha chain-dependent pathway. This pathway may underlie the genetic associations of asthma with both the human 5q31 locus and the IL-4 receptor.
Figures
Fig. 1
PAS-stained histologic sections of murine lungs. Arrowheads point to goblet cells within the respiratory epithelium. (A) Wild-type mice were primed with OVA and challenged with PBS intranasally. (B) Wild-type mice were administered IL-13 intranasally. (C) IL-4–deficient and (D) IL-4Rα–deficient mice were primed with OVA and challenged with OVA intranasally. Wild-type mice were primed with OVA and challenged intranasally with (E) OVA and human Fc control protein or with (F) OVA and IL-13R-Fc. Note the marked reduction in goblet cells in (D) and (F).
Fig. 2
Effect of neutralization of IL-13. Primed wild-type mice were administered intranasally human immunoglobulin (Ig control), Ig control and OVA, or IL-13R-Fc and OVA as indicated by (+). Data for (A) AHR, (B) goblet cell score, and numbers of (C) eosinophils and (D) neutrophils in the BAL fluid are plotted as means ± SEM. *P < 0.05 relative to PBS and Ig control–treated mice; †P < 0.05 relative to OVA and Ig control–treated mice. Data are representative of at least two comparable experiments with four to eight mice per group.
Fig. 3
Effect of recombinant IL-4 and IL-13. Wild-type (WT), RAG1-deficient (RAG1−/−), and IL-4Rα–deficient (IL-4Rα−/−) mice were administered IL-4, IL-13, or control protein intranasally. Data for (A) AHR, (B) goblet cell score, and numbers of (C) eosinophils and (D) neutrophils in the BAL fluid are plotted as means ± SEM. *P < 0.05 relative to mice receiving control protein. Data are representative of at least two comparable experiments with four to eight mice per group.
Comment in
- Interleukin-13's key role in asthma shown.
Vogel G. Vogel G. Science. 1998 Dec 18;282(5397):2168. doi: 10.1126/science.282.5397.2168a. Science. 1998. PMID: 9890820 No abstract available.
Similar articles
- Interleukin-13: central mediator of allergic asthma.
Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Wills-Karp M, et al. Science. 1998 Dec 18;282(5397):2258-61. doi: 10.1126/science.282.5397.2258. Science. 1998. PMID: 9856949 - Cytokine regulation of mucus production in a model of allergic asthma.
Cohn L, Whittaker L, Niu N, Homer RJ. Cohn L, et al. Novartis Found Symp. 2002;248:201-13; discussion 213-20, 277-82. Novartis Found Symp. 2002. PMID: 12568496 - Atopy and asthma: genetic variants of IL-4 and IL-13 signalling.
Shirakawa I, Deichmann KA, Izuhara I, Mao I, Adra CN, Hopkin JM. Shirakawa I, et al. Immunol Today. 2000 Feb;21(2):60-4. doi: 10.1016/s0167-5699(99)01492-9. Immunol Today. 2000. PMID: 10652462 Review. No abstract available. - Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice?
Leigh R, Ellis R, Wattie J, Donaldson DD, Inman MD. Leigh R, et al. Am J Respir Crit Care Med. 2004 Oct 15;170(8):851-6. doi: 10.1164/rccm.200311-1488OC. Epub 2004 Jul 8. Am J Respir Crit Care Med. 2004. PMID: 15242841 - Recent advances in understanding how interleukin 13 signals are involved in the pathogenesis of bronchial asthma.
Izuhara K, Umeshita-Suyama R, Akaiwa M, Shirakawa T, Deichmann KA, Arima K, Hamasaki N, Hopkin JM. Izuhara K, et al. Arch Immunol Ther Exp (Warsz). 2000;48(6):505-12. Arch Immunol Ther Exp (Warsz). 2000. PMID: 11197605 Review.
Cited by
- Anti-astmatic effect of ROCK inhibitor, GSK429286 A, in experimentally induced allergic airway inflammation.
Gondáš E, Mažerik J, Dohál M, Bálentová S, Pokusa M, Vargová D, Smieško L, Šutovská M, Jošková M, Fraňová S. Gondáš E, et al. Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241282949. doi: 10.1177/03946320241282949. Int J Immunopathol Pharmacol. 2024. PMID: 39305209 Free PMC article. - Diacylglycerol kinase is a keystone regulator of signaling relevant to the pathophysiology of asthma.
Hernandez-Lara MA, Richard J, Deshpande DA. Hernandez-Lara MA, et al. Am J Physiol Lung Cell Mol Physiol. 2024 Jul 1;327(1):L3-L18. doi: 10.1152/ajplung.00091.2024. Epub 2024 May 14. Am J Physiol Lung Cell Mol Physiol. 2024. PMID: 38742284 Review. - Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies.
Gutiérrez-Vera C, García-Betancourt R, Palacios PA, Müller M, Montero DA, Verdugo C, Ortiz F, Simon F, Kalergis AM, González PA, Saavedra-Avila NA, Porcelli SA, Carreño LJ. Gutiérrez-Vera C, et al. Front Immunol. 2024 Apr 2;15:1364774. doi: 10.3389/fimmu.2024.1364774. eCollection 2024. Front Immunol. 2024. PMID: 38629075 Free PMC article. Review. - The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
Russell RJ, Boulet LP, Brightling CE, Pavord ID, Porsbjerg C, Dorscheid D, Sverrild A. Russell RJ, et al. Eur Respir J. 2024 Apr 4;63(4):2301397. doi: 10.1183/13993003.01397-2023. Print 2024 Apr. Eur Respir J. 2024. PMID: 38453256 Free PMC article. Review. - The Importance of Th2 Immune Responses in Mediating the Progression of Gastritis-Associated Metaplasia to Gastric Cancer.
Privitera G, Williams JJ, De Salvo C. Privitera G, et al. Cancers (Basel). 2024 Jan 25;16(3):522. doi: 10.3390/cancers16030522. Cancers (Basel). 2024. PMID: 38339273 Free PMC article. Review.
References
- Molfino NA, Nannini LJ, Martelli AN, Slutsky AS. N. Engl. J. Med. 1991;324:285. - PubMed
- Goldstein RA, Paul WE, Metcalfe DD, Busse WW, Reece ER. Ann. Intern. Med. 1994;121:698. - PubMed
- Gavett SH, Chen X, Finkelman F, Wills-Karp M. Am. J. Respir. Cell Mol. Biol. 1994;10:587. - PubMed
- Watanabe A, et al. ibid. 1997;16:69. - PubMed
- Garssen J, Nijkamp FP, Van Der Vliet H, Van Loveren H. Am. Rev. Respir. Dis. 1991;144:931. - PubMed
- Rankin JA, et al. Proc. Natl. Acad. Sci. U.S.A. 1996;93:7821. - PubMed
- Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. J. Exp. Med. 1996;183:195. - PMC - PubMed
- Mauser PJ, et al. Am. Rev. Respir. Dis. 1993;148:1623. - PubMed
- Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R. Am. J. Respir. Cell Mol. Biol. 1995;12:254. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K08 HL003344/HL/NHLBI NIH HHS/United States
- P50 HL056385/HL/NHLBI NIH HHS/United States
- T32 HL007185/HL/NHLBI NIH HHS/United States
- 03344/PHS HHS/United States
- 47412/PHS HHS/United States
- T32 HL07185/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous